Promising Results from Study but More Work Needed for Healthcare Equity in Kenya

By Staff Writer

August 31, 2023

The African Health Markets for Equity (AHME) program has shown encouraging results in improving access to and quality of private health clinics in Kenya, according to a recent study. The research, a cluster randomised controlled trial, aimed to determine if the combination of social health insurance and management training could enhance healthcare services in the country.

The study revealed that AHME significantly impacted clinics, with the treatment group reporting a 26.0% increase in total clients and a 51.3% increase in National Hospital Insurance Fund (NHIF) clients. AHME also increased the likelihood of individuals having any form of health insurance, whether public or private.

However, the study did not find that AHME was successful in promoting pro-poor private healthcare. Poor households were significantly less likely to have health insurance, and there was no additional effect of AHME for this group. The study also found that AHME did not improve the quality of care for poor clients.

AHME focused on social health insurance as a mechanism for low-income households to receive high-quality healthcare at private or public clinics. The intervention encouraged and assisted private clinics to register under the NHIF scheme. This resulted in large effects on clinic registration and significant increases in the number of clients with public insurance served.

Despite these positive outcomes, more work is needed to improve insurance enrollment for poorer households. The study suggests that future research should focus on understanding the mechanisms through which increased clinic NHIF registration might increase demand-side insurance enrollment.

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.